

'Pharmatizing' AI in Life Sciences

September 28, 2023



Scott Snyder
Chief Digital Officer





Shakthi Kumar

Worldwide Head, Healthcare and Life Sciences Industry Specialists





Agenda

- Three Things to Know About Al
- 'Pharmatizing' AI Impact
- Turning a Vision into Reality
- Advice



Three Key Things to Know About Al

Al Is Not New, But GenAl Has Accelerated Al



GenAl Has Moved To The Foreground

ChatGPT is the fastest growing app in history and has enabled non-techies to play with Al directly to solve both everyday and creative tasks.



Al Is Changing How We Operate

Al has the potential to reduce time/resources by 50-80% for activities like software coding, QA, content creation, info search, and customer service.




Al Is About Humans

Issues with reliability and hallucinations make "human-in-the-loop" essential, along with using AI as the ultimate "sidekick" for employees.



The Interest and Expectations are Rising Fast...





But Not Without Risks...





EVERSANA & Amazon Web Services to "Pharmatize" Artificial Intelligence Across the Life Sciences Industry

Together the organizations aim to transform pharmaceutical operations and accelerate patient impact







Generative AI Use Cases for Life Sciences Commercialization

	Pre-Launch	Launch	Post-Launch
Commercial Excellence	 Automated Content Generation, Review and Dissemination Synthetic Data for HCP and Patient Targeting 	 Field Conversational Assistants with Sales Insights and HCP Intelligence Omnichannel Next Best Action and Personalization 	 Patient Support Assist Enrolment, Benefits and PA verification Patient Self-service/Chatbot
Market Access	 Pricing and Reimbursement Modelling Market and Competitor Insights 	 Marketing Mix Suggestions and Optimization Patient Journey Analysis/Insights 	Automated Assistance on Immediate Labelling Changes
Regulatory	 Messaging, Sales Aid and Concept Regulatory Verification 	 Dossier Submission Summary by Region 	Med Literature Review/Monitoring
Medical Affairs	 Target Product Profile Summary and Optimization 	 Personalized Learning and Development Platform for HCPs and Sales Reps 	Synthetic Data Generation for RWE Observational Studies Support



What 'Pharmatizing' Al Means & How To Prepare

Unlocking the full potential of Al Innovation while effectively managing risk for life science companies and their patients

- Have a responsible and ethical Al development framework that aligns with the core values of the company and communicate broadly
- Establish a cross-company Al-council/governance model to help coordinate opportunities and manage risks
- Identify and prioritize use cases based on potential business and end-user impact as well as the ability to deploy at scale and manage risk
- Evolve the technology stack, data assets, and partner ecosystem to enable "best of breed" Al solutions to meet the unique need of target use cases
- 5 Engage the broader employee base on Al literacy and co-creation of new Al innovations
- Create a "sandbox" to enable rapid innovation and validation of new Al models that can securely access company data and content
- Be aware of the life cycle costs required to deploy LLMs at scale They can be significant. Bigger is not always better for Al models trained on content for specialized domains.



Vision to Reality

Example Use Case





Accelerate MLR Process with Al

Transforming the medical, legal and regulatory review processes with AI to deliver a faster, more efficient approach to developing and delivering content for sales, marketing and payer efforts.



Advice for Pharma



Align

- Responsible/ethical development framework
- Governance model
- Tech and data foundation and sandboxes
- Leader and workforce Al literacy and engagement



Innovate

- Prioritize target use cases based on impact and viability/risk
- Co-create AI solutions with employees and partners
- Validate experience/benefit with lead users
- Validate business case/impact



Scale

- Productize validated Al solutions
- Measure/publish success cases
- Optimize/retrain AI models
- Manage/monitor on-going performance/risk



QUESTIONS?



THANK YOU

